Natural Products As Drug Candidates for Breast Cancer (Review)

Overview

Journal Oncol Lett

Specialty Oncology

Date 2023 Jul 10

PMID 37427344

Authors

Nitin T Telang

Affiliations

Soon will be listed here.

Abstract

Progression of early-stage breast cancer to advanced-stage metastatic disease represents a major cause of death in women. Long-term conventional and targeted therapy for breast cancer includes multi-drug combinations of cytotoxic chemotherapeutics and pathway-selective small molecule inhibitors. These treatment options are frequently associated with systemic toxicity, intrinsic/acquired therapy resistance and emergence of a drug-resistant cancer stem cell population. This stem cell population has a chemo-resistant, cancer-initiating, premalignant phenotype that is accompanied by cellular plasticity and metastatic potential. These limitations emphasize an unmet need to identify testable alternatives against therapy-resistant metastatic breast cancer. Natural products such as dietary phytochemicals, nutritional herbs and their constitutive bioactive agents have documented human consumption, and lack detectable systemic toxicity and resultant off-target unfavorable side effects. Because of these advantages, natural products may represent testable alternatives for therapy-resistant breast cancer. The present review discusses published evidence for growth inhibitory efficacy of natural products on cellular models for molecular subtypes of clinical breast cancer and development of drug-resistant stem cell models. Collectively, this evidence validates mechanism-based experimental approaches to screen and prioritize efficacious bioactive agents from natural products as novel drug candidates that may function as therapeutic alternatives for breast cancer.

Citing Articles

Anti‑proliferative effects of in a model for triple negative breast cancer.

Telang N, Nair H, Wong G Oncol Lett. 2024; 29(2):91.

PMID: 39691588 PMC: 11650959. DOI: 10.3892/ol.2024.14837.

Green synthesized extracts/Au complex of : Unrevealing the anti-cancer and anti-bacterial potentialities, supported by metabolomics and molecular modeling.

Aati S, Aati H, El-Shamy S, Khanfar M, A Naeim M, Hamed A Heliyon. 2024; 10(13):e34000.

PMID: 39071630 PMC: 11283168. DOI: 10.1016/j.heliyon.2024.e34000.

Oxyresveratrol in Breast Cancer Cells: Synergistic Effect with Chemotherapeutics Doxorubicin or Melphalan on Proliferation, Cell Cycle Arrest, and Cell Death.

Passos C, Ferreira C, de Carvalho A, Silva J, Garrett R, Fialho E Pharmaceutics. 2024; 16(7).

PMID: 39065570 PMC: 11279446. DOI: 10.3390/pharmaceutics16070873.

Exploring the potential of tocopherols: mechanisms of action and perspectives in the prevention and treatment of breast cancer.

Nava-Tapia D, Roman-Justo N, Cuenca-Rojo A, Guerrero-Rivera L, Patron-Guerrero A, Poblete-Cruz R Med Oncol. 2024; 41(9):208.

PMID: 39060448 DOI: 10.1007/s12032-024-02454-x.

Synthesis, pharmacological evaluation, and study of new 3-furan-1-thiophene-based chalcones as antibacterial and anticancer agents.

Abdula A, Mohsen G, Jasim B, Jabir M, Rushdi A, Baqi Y Heliyon. 2024; 10(11):e32257.

PMID: 38947436 PMC: 11214363. DOI: 10.1016/j.heliyon.2024.e32257.

References

Sabnis G, Brodie A . Understanding resistance to endocrine agents: molecular mechanisms and potential for intervention. Clin Breast Cancer. 2010; 10(1):E6-E15. DOI: 10.3816/CBC.2010.n.014. View

Ye L, Jia Y, Ji K, Sanders A, Xue K, Ji J . Traditional Chinese medicine in the prevention and treatment of cancer and cancer metastasis. Oncol Lett. 2015; 10(3):1240-1250. PMC: 4533180. DOI: 10.3892/ol.2015.3459. View

Arzi L, Mollaei H, Hoshyar R . Countering Triple Negative Breast Cancer via Impeding Wnt/β-Catenin Signaling, a Phytotherapeutic Approach. Plants (Basel). 2022; 11(17). PMC: 9460573. DOI: 10.3390/plants11172191. View

Telang N . The Divergent Effects of Ovarian Steroid Hormones in the MCF-7 Model for Luminal A Breast Cancer: Mechanistic Leads for Therapy. Int J Mol Sci. 2022; 23(9). PMC: 9105252. DOI: 10.3390/ijms23094800. View

Sorlie T, Perou C, Tibshirani R, Aas T, Geisler S, Johnsen H . Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98(19):10869-74. PMC: 58566. DOI: 10.1073/pnas.191367098. View

Suto , Telang , Tanino , Takeshita , Ohmiya , Osborne . In Vitro and In Vivo Modulation of Growth Regulation in the Human Breast Cancer Cell Line MCF-7 by Estradiol Metabolites. Breast Cancer. 2000; 6(2):87-92. DOI: 10.1007/BF02966913. View

Rushing B, Wiggs A, Molina S, Schroder M, Sumner S . Metabolomics Analysis Reveals Novel Targets of Chemosensitizing Polyphenols and Omega-3 Polyunsaturated Fatty Acids in Triple Negative Breast Cancer Cells. Int J Mol Sci. 2023; 24(5). PMC: 10002396. DOI: 10.3390/ijms24054406. View

Gupta M, McDougal A, Safe S . Estrogenic and antiestrogenic activities of 16alpha- and 2-hydroxy metabolites of 17beta-estradiol in MCF-7 and T47D human breast cancer cells. J Steroid Biochem Mol Biol. 1999; 67(5-6):413-9. DOI: 10.1016/s0960-0760(98)00135-6. View

Manogaran P, Umapathy D, Karthikeyan M, Venkatachalam K, Singaravelu A . Dietary Phytochemicals as a Potential Source for Targeting Cancer Stem Cells. Cancer Invest. 2021; 39(4):349-368. DOI: 10.1080/07357907.2021.1894569. View

10.

Moy B, Goss P . Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches. Clin Cancer Res. 2006; 12(16):4790-3. DOI: 10.1158/1078-0432.CCR-06-1535. View

11.

Telang N, Nair H, Wong G . Growth inhibitory efficacy and anti-aromatase activity of in a model for post-menopausal Luminal A breast cancer. Biomed Rep. 2019; 11(5):222-229. PMC: 6792322. DOI: 10.3892/br.2019.1244. View

12.

Patel S, Ndabahaliye A, Lim P, Milton R, Rameshwar P . Challenges in the development of future treatments for breast cancer stem cells. Breast Cancer (Dove Med Press). 2014; 2:1-11. PMC: 3004231. View

13.

Kumar V, Nambiar R, De Souza C, Nguyen A, Chien J, Lam K . Targeting Epigenetic Modifiers of Tumor Plasticity and Cancer Stem Cell Behavior. Cells. 2022; 11(9). PMC: 9102449. DOI: 10.3390/cells11091403. View

14.

Velloso F, Bianco A, Farias J, Torres N, Ferruzo P, Anschau V . The crossroads of breast cancer progression: insights into the modulation of major signaling pathways. Onco Targets Ther. 2017; 10:5491-5524. PMC: 5701508. DOI: 10.2147/OTT.S142154. View

15.

Telang N . Anti-proliferative and pro-apoptotic effects of rosemary and constituent terpenoids in a model for the HER-2-enriched molecular subtype of clinical breast cancer. Oncol Lett. 2018; 16(4):5489-5497. PMC: 6126163. DOI: 10.3892/ol.2018.9238. View

16.

Telang N, Nair H, Wong G . Growth Inhibitory Efficacy of Chinese Herbs in a Cellular Model for Triple-Negative Breast Cancer. Pharmaceuticals (Basel). 2021; 14(12). PMC: 8708199. DOI: 10.3390/ph14121318. View

17.

Bruna A, Rueda O, Greenwood W, Batra A, Callari M, Batra R . A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. Cell. 2016; 167(1):260-274.e22. PMC: 5037319. DOI: 10.1016/j.cell.2016.08.041. View

18.

Lytle N, Barber A, Reya T . Stem cell fate in cancer growth, progression and therapy resistance. Nat Rev Cancer. 2018; 18(11):669-680. PMC: 8388042. DOI: 10.1038/s41568-018-0056-x. View

19.

Relitti N, Saraswati A, Federico S, Khan T, Brindisi M, Zisterer D . Telomerase-based Cancer Therapeutics: A Review on their Clinical Trials. Curr Top Med Chem. 2020; 20(6):433-457. DOI: 10.2174/1568026620666200102104930. View

20.

Cox L, Chen G, Lee E . Tumor suppressor genes and their roles in breast cancer. Breast Cancer Res Treat. 1994; 32(1):19-38. DOI: 10.1007/BF00666203. View